Stock Update (NASDAQ:ACRX): AcelRx Pharmaceuticals Inc Brings on Two More Acute Pain Experts to Analyst and Investor Event

AcelRx Pharmaceuticals Inc (NASDAQ: ACRX) announced an update to the agenda for its December 1, 2016 Analyst & Investor Event. Dr. Nathaniel Katz, CEO of Analgesic Solutions and Adjunct Assistant Professor at Tufts University along with Dr. David Leiman, president of AIPM of Houston and Director of HD Research Corp., have been added to the agenda to offer their insights into the ARX-04 clinical program, regulatory pathway, market opportunity and the current treatment of acute pain.

Full Agenda of Expert Speakers

  • Nathaniel Katz, MD; CEO of Analgesic Solutions, Adjunct Assistant Professor of Anesthesia at Tufts University School of Medicine;
  • David Leiman, MD; President of AIPM of Houston and Director of HD Research Corp.;
  • John Holcomb, MD; Chief of the Division of Acute Care Surgery, University of Texas Health Science Center, Houston, TX;
  • James Miner, MD; Chief of Emergency Medicine, Hennepin County Medical Center, Minneapolis, MN; and
  • Michael Ritter, MD Emergency Medicine Physician, St. Joseph Health Mission Hospital, Mission Viejo, CA.

Dr. Katz is considered to be one of the leading experts on the treatment of pain and the design of clinical trials to assess pain therapies. He founded Analgesic Solutions in 2007 with the aim of modernizing the design and conduct of pain clinical trials, to advance the scientific quality of clinical research, and to empower effective treatments for patients. Dr. Katz is also an Adjunct Assistant Professor of Anesthesia at Tufts University School of Medicine. Dr. Katz was previously chair of the Advisory Committee, Anesthesia, Critical Care and Addiction Products Division of the FDA.  During the Analyst & Investor Event, Dr. Katz will provide his insights into the approval pathway for opioids.

Dr. Leiman founded and operates AIPM of Houston, a company that provides anesthesia and interventional pain services, and is Director of HD Research Corp., a company that specializes in inpatient acute pain clinical research. He has been involved in the ARX-04 clinical program and will present an integrated summary of efficacy and safety along with a review of the clinical results from the emergency room study, SAP302. Dr. Leiman replaces Dr. Harold Minkowitz, who was previously announced as a speaker. (Original Source)

Shares of AcelRX are trading at $2.99, down $0.06 or -1.90%. ACRX has a 1-year high of $5.85 and a 1-year low of $2.40. The stock’s 50-day moving average is $3.41 and its 200-day moving average is $3.29.

On the ratings front, AcelRX Pharmaceuticals has been the subject of a number of recent research reports. In a report issued on November 2, H.C. Wainwright analyst Ed Arce reiterated a Buy rating on ACRX. Separately, on the same day, Roth Capital’s Michael Higgins reiterated a Buy rating on the stock and has a price target of $15.

According to, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Ed Arce and Michael Higgins have a yearly average return of 4.6% and a loss of 11.0% respectively. Arce has a success rate of 35% and is ranked #1055 out of 4245 analysts, while Higgins has a success rate of 33% and is ranked #4037.

Overall, one research analyst has assigned a Hold rating and 3 research analysts have given a Buy rating to the stock. When considering if perhaps the stock is under or overvalued, the average price target is $7.00 which is 129.5% above where the stock closed last Friday.

AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company that focuses on the development and commercialization of therapies for the treatment of actual pain. Its lead product candidate includes ZalvisoTM intended for the management of moderate-to-severe acute pain in hospitalized adult patients. Zalviso consists of sufentanil sublingual tablets delivered by the Zalviso System, a needle-free, handheld, patient-administered, pain management system. It is designed to address the problems associated with post-operative intravenous patient-controlled analgesia, or IV PCA. 

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts